FindTrial
Sign In

Prediction of symptomatic response to galantamine treatment by regional cerebral blood flow measurement in Alzheimer's disease patients.

Prediction of symptomatic response to galantamine treatment by regional cerebral blood flow measurement in Alzheimer's disease patients. - The response to galantamine in Alzheimer's disease patients.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000011135
Enrollment
60
Registered
2013-07-08
Start date
2012-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer&#39

Interventions

Object:Patients with mild to moderate Alzheimer&#39
s disease. Duration:1 year Drug:galantamine Evaluation:Cerebral blood flow with ECD-SPECT, ADAS-J cog, MMSE at each time point.

Sponsors

Toho University, Ohashi Medical Center, Department of Neurosurgery
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Age older than 65 years old. Diagnosed as mild to moderate Alzheimer's disease. Non medicated.

Exclusion criteria

Exclusion criteria: Severe Alzheimer's disease Dementia with Lewy body Frontal-temporal type dementia Vascular dementia Sixty-five years old and younger With a history of medication with anti-dementia drug

Design outcomes

Primary

MeasureTime frame
Neurological test: ADAS-J Cog, MMSE rCBF measurement using SPECT—

Countries

Japan

Contacts

Public ContactYoko Hirata

Toho university medical center, Ohashi hospital Department of Neurosurgery

yokochan3@gmail.com03-3481-7319

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026